Tregliptin is a long-acting DPP-4 inhibitor, which is used for the treatment of type 2 diabetes. It is necessary to pay attention to the key information such as the special drug users, dosage adjustment and potential drug interactions.

1. Usage and dosage

(1) The recommended dosage for adults is 100mg orally once a week, which can be taken before or after meals.

(2) Patients with renal insufficiency need to adjust the dosage: reduce it to 50mg/week for moderate impairment, and discontinue it for severe impairment.

2. Medication for special populations

(1) Pregnant women: Animal studies have shown embryotoxicity, avoid use during pregnancy.

(2) Breastfeeding period: Medication may be secreted into breast milk, it is recommended to suspend breastfeeding during the medication period.

(3) Children: Safety and efficacy data have not been established yet, and it is not recommended to use it.

(4) Elderly individuals: No need to adjust dosage, but need to monitor changes in kidney function.

3 drug interactions

(1) Combined use with insulin or sulfonylureas may increase the risk of hypoglycemia and require dosage adjustment.

(2) Strong CYP3A4 inducers may reduce the blood concentration of quercetin.

(3) Be alert to the risk of dehydration when using diuretics in combination.

4 Precautions

(1) Regular monitoring of blood glucose and glycated hemoglobin levels is required during medication.

(2) If there are persistent symptoms of pancreatitis such as vomiting and abdominal pain, the medication should be stopped immediately.

(3) Severe allergic reactions (such as angioedema) require permanent discontinuation.

(4) Patients with liver function impairment do not need to adjust the dosage, but those with severe impairment should use it with caution.